The PolyU Advanced Therapy Product (ATP) Laboratory is a Pharmaceutical Inspection Co-operation Scheme’s Good Manufacturing Practice (PIC/S GMP)-compliant facility, focusing on clinical research in immunotherapy, cell therapy, gene therapy and regenerative medicine. Equipped with a Production Site, Quality Control Laboratory and Training Laboratory, the Laboratory will serve as a robust platform for the development and clinical application of local ATPs. The ATP team, in collaboration with scientific research enterprises, the biopharmaceutical industry, and academic institutions, will focus on clinical trials for spinal cord injury patients during its first phase of work. It will make use of human leukocyte antigen (HLA)-matched umbilical cord blood received from the industry partner to produce umbilical cord blood-derived mononuclear cells. Quality control and product packaging procedures will also be performed. PIC/S GMP-compliant final products will then be sent to the hospitals for transplantation in patients.